Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors

References

• Takakura M, Kyo S, Sowa Y, et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 2001;29:3006–3011.
   PubMed Web of Science ®Google Scholar
• Galvani A, Thiriet C. Nucleosome dancing at the tempo of histone tail acetylation. Genes. 2015;6(3):607–621.
   PubMed Web of Science ®Google Scholar
• Chao S, Chen C, Chen L, et al. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. Eur J Med Chem. 2018;143:792–805.
   PubMed Web of Science ®Google Scholar
• Pasini A, Marchetti C, Sissi C, et al. Novel polyamine-naphthalene diimide conjugates targeting histone deacetylases and DNA for cancer phenotype reprogramming. Acs Med Chem Lett. 2017;8(12):1218–1223.
   PubMed Web of Science ®Google Scholar
• Meng Q, Liu Z, Li F, et al. An HDAC-targeted imaging probe LBH589-Cy5.5 for tumor detection and therapy evaluation. Mol Pharm. 2015;12(7):2469–2476.
   PubMedGoogle Scholar
• Wang X, Wan RZ, Liu ZP. Recent advances in the discovery of potent and selective HDAC6 inhibitors. Eur J Med Chem. 2018;143:1406–1418.
   PubMed Web of Science ®Google Scholar
• Woan KV, Lienlaf M, Perez-Villaroel P, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015;9(7):1447–1457.
   PubMed Web of Science ®Google Scholar
• Shuai T, Feng H, Tingting K, et al. Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors. Bioorg Med Chem. 2017;25(15):4123–4132.
   PubMed Web of Science ®Google Scholar
• Leonhardt M, Sellmer A, Krämer OH, et al. Design and biological evaluation of tetrahydr-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. Eur J Med Chem. 2018;152:329–357.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang T, Wang F, et al. Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer. J Med Chem. 2015;59:302–305.
   Google Scholar
• Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 2012;4:505–524.
   PubMed Web of Science ®Google Scholar
• Reid T, Valone F, Lipera W, et al. Phase Ⅱ trail of the histone deacetylase inhibitor pivaloyloxymethylbutyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45:381–386.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101),a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4:97–101.
   PubMed Web of Science ®Google Scholar
• Mackay H, Hirte H, Colgan T, et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur J Cancer. 2010;46:1573–1579.
   PubMed Web of Science ®Google Scholar
• Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Invest Drugs. 2011;20:823–829.
   PubMed Web of Science ®Google Scholar
• Fraczek J, Vanhaecke T, Rogiers V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol. 2013;9:441–457.
   PubMed Web of Science ®Google Scholar
• Ma N, Luo Y, Wang Y, et al. Selective histone deacetylase inhibitors with anticancer activity. Curr Top Med Chem. 2016;16:415–426.
   PubMed Web of Science ®Google Scholar
• Seidel C, Schnekenburger M, Dicato M, et al. Histone deacetylase 6 in health and disease. Epigenomics. 2015;7:103–118.
   PubMed Web of Science ®Google Scholar
• Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem. 2016;121:451–483.
   PubMed Web of Science ®Google Scholar
• Sun Q, Yao Y, Liu C, et al. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. Bioorg Med Chem Lett. 2013;23(11):3295–3299.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li L, Min J. Structural biology: HDAC6 finally crystal clear. Nat Chem Biol. 2016;12:660–661.
   PubMed Web of Science ®Google Scholar
• Hua Z, Yiqin W, Marc N, et al. Characterization of the two catalytic domains in histone deacetylase 6. Biochem Biophys Res Commun. 2006;341:45–50.
   PubMed Web of Science ®Google Scholar
• Kalin JH, Bergman JA. Development and therapeutic implications of selective histone deacetylase 6 inhibitors. J Med Chem. 2013;56(6):6297–6373.
   PubMedGoogle Scholar
• Claudia PM, Kechen B, Melanie ED, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood. 2007;110(1):267–277.
   PubMed Web of Science ®Google Scholar
• Boyault C, Sadoul K, Pabion M, et al. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007;26(37):5468–5476.
   PubMed Web of Science ®Google Scholar
• Kalin JH, Butler KV, Kozikowski AP. Creating zinc monkey wrenches in the treatment of epigenetic disorders. Curr Opin Chem Biol. 2009;13:263–271.
   PubMed Web of Science ®Google Scholar
• Bulter KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des. 2008;14:505–528.
   PubMed Web of Science ®Google Scholar
• Mai A, Massa S, Rotili D, et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Let. 2005;15(21):4656–4661.
   PubMed Web of Science ®Google Scholar
• Arif MA, Abbasi SZ, Siddiqui S, et al. Synthesis and pharmacological screening: sulfa derivatives of 2-pipecoline-bearing 1,3,4-oxadiazole core. Russ J Bioorg Chem. 2017;43(3):328–339.
   Google Scholar
• Mahmoud M, Mohammed I, Mohammed S, et al. Synthesis and invitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety. Eur J Med Chem. 2015;90:45–52.
   PubMed Web of Science ®Google Scholar
• Frey RR, Wada CK, Garland RB, et al. Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002;12:3331–3335.
   Web of Science ®Google Scholar